1991
The calculation of actual or received dose intensity: a comparison of published methods.
Longo D, Duffey P, DeVita V, Wesley M, Hubbard S, Young R. The calculation of actual or received dose intensity: a comparison of published methods. Journal Of Clinical Oncology 1991, 9: 2042-51. PMID: 1941063, DOI: 10.1200/jco.1991.9.11.2042.Peer-Reviewed Original ResearchConceptsSouthwest Oncology GroupTreatment courseEntire treatment coursePatient's treatment coursePrognostic factorsTreatment outcomesAggressive histology lymphomaCombination chemotherapy programsClinical prognostic factorsNational Cancer Institute studyDistinct patient populationsDose-related variablesDose intensityOncology GroupChemotherapy programPrognostic significancePatient populationStudy populationInstitute studyOutcomesRecent reportsEntire populationPopulationCourseDI dataTreatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo D, Duffey P, DeVita V, Wiernik P, Hubbard S, Phares J, Bastian A, Jaffe E, Young R. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Journal Of Clinical Oncology 1991, 9: 1409-20. PMID: 1712836, DOI: 10.1200/jco.1991.9.8.1409.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinDose-Response Relationship, DrugDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaLomustineMaleMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission InductionStreptozocinSurvival RateVincristineConceptsAdvanced-stage Hodgkin's diseaseErythrocyte sedimentation rateDose intensityOverall survivalHodgkin's diseaseInitial erythrocyte sedimentation rateDisease-free survival ratesDisease-free survival curvesComplete response rateDisease-free survivalBetter overall survivalPoor prognostic factorSecondary acute leukemiaHigher platelet countsAssessable patientsPrognostic factorsPlatelet countAcute leukemiaTreatment outcomesMOPPPatientsResponse rateSurvival rateSurvival curvesDisease
1988
The role of chemotherapy in diffuse aggressive lymphomas.
DeVita V, Hubbard S, Young R, Longo D. The role of chemotherapy in diffuse aggressive lymphomas. Seminars In Hematology 1988, 25: 2-10. PMID: 3041598.Peer-Reviewed Original ResearchConceptsDiffuse aggressive lymphomasEarly-stage diseaseCombination chemotherapyAggressive lymphomaDose intensityNew combination chemotherapy programScheduling of drugsDurable complete remissionRole of chemotherapyCombination chemotherapy programsImportant prognostic factorEnd of treatmentComplete remissionStage diseaseChemotherapy programPrognostic factorsSubsequent radiotherapyRisk factorsPrimary treatmentAdditional drugsChemotherapyOld drugsAdvanced stageLymphomaRadiotherapy
1982
Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer institute
Anderson T, Devita V, Simon R, Berard C, Canellos G, Garvin A, Young R. Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer institute. Cancer 1982, 50: 2708-2721. PMID: 7139564, DOI: 10.1002/1097-0142(19821215)50:12<2708::aid-cncr2820501203>3.0.co;2-g.Peer-Reviewed Original ResearchConceptsHistologic typeDiffuse histologic typeComplete responseNational Cancer InstitutePrognostic factorsLymphoma patientsLymphocytic lymphomaCancer InstituteHigh complete response rateDiffuse lymphoma patientsModern radiotherapeutic techniquesNodular lymphocytic lymphomaNodular lymphoma patientsSimilar treatment regimensComplete response rateImportant prognostic factorStage of diseaseCS ICS IIICS IVB symptomsCombination chemotherapyIV patientsHistologic subtypePatient sex
1981
Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.
Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981, 58: 45-51. PMID: 7236892, DOI: 10.1182/blood.v58.1.45.bloodjournal58145.Peer-Reviewed Original ResearchConceptsLong-term survivalHuge abdominal massGastrointestinal involvementAbdominal massCurrent therapiesExcellent long-term survivalBone marrow statusBone marrow involvementSubset of patientsCases of diffuseMarrow statusConstitutional symptomsMarrow involvementMedian survivalHepatic involvementPrognostic factorsClinical factorsUndifferentiated lymphomaMale sexPatient survivalSerum LDHHistopathologic materialPatient groupPoor prognosisClinical trialsFactors Predicting Long-Term Survival in Diffuse Mixed, Histiocytic, or Undifferentiated Lymphoma
Fisher R, Hubbard S, DeVita V, Berard C, Wesley R, Cossman J, Young R. Factors Predicting Long-Term Survival in Diffuse Mixed, Histiocytic, or Undifferentiated Lymphoma. Blood 1981, 58: 45-51. DOI: 10.1182/blood.v58.1.45.45.Peer-Reviewed Original ResearchLong-term survivalHuge abdominal massGastrointestinal involvementAbdominal massCurrent therapiesPredicting Long-Term SurvivalExcellent long-term survivalBone marrow statusBone marrow involvementSubset of patientsCases of diffuseMarrow statusConstitutional symptomsMarrow involvementMedian survivalHepatic involvementPrognostic factorsClinical factorsUndifferentiated lymphomaMale sexPatient survivalSerum LDHHistopathologic materialPatient groupPoor prognosis
1980
The evolution of primary multimodality treatment in resectable breast cancer
Henney J, Devita V. The evolution of primary multimodality treatment in resectable breast cancer. Cancer 1980, 46: 999-1008. PMID: 6994877, DOI: 10.1002/1097-0142(19800815)46:4+<999::aid-cncr2820461325>3.0.co;2-e.Peer-Reviewed Original ResearchConceptsDisease-free intervalPremenopausal womenClinical trialsBreast cancerProspective randomized clinical trialsStage II breast cancerAdjuvant therapy studiesResectable breast cancerRandomized clinical trialsNational Cancer InstitutePositive resultsPostmenopausal womenMultimodality treatmentPostoperative periodPrognostic factorsNational mortalityClinical dataEstrogen receptorDrug doseCancer InstituteStage IClinical researchPatientsTherapy studiesTrials
1977
Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy
Fisher R, DeVita V, Johnson B, Simon R, Young R. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. The American Journal Of Medicine 1977, 63: 177-182. PMID: 70170, DOI: 10.1016/0002-9343(77)90230-3.Peer-Reviewed Original Research
1974
The design of clinical trials in the therapy of ovarian carcinoma
Young R, DeVita V. The design of clinical trials in the therapy of ovarian carcinoma. American Journal Of Obstetrics And Gynecology 1974, 120: 1012-1024. PMID: 4432892, DOI: 10.1016/0002-9378(74)90143-4.Peer-Reviewed Original ResearchConceptsOvarian carcinomaClinical trialsProspective randomized clinical trialsSurvival of patientsCombined modality approachRandomized clinical trialsPrognostic factorsStandardized stagingModality approachTherapySuch trialsCarcinomaMajor causeTrialsPatientsBase lineSurvivalChemotherapyRadiotherapyStagingWomen